Akston Biosciences

General Information
Business:	(Incorporated in Delaware) We are a pet biotech company developing and commercializing innovative biologic therapies – specifically, antibody and protein therapies – for cats, dogs and other companion animals. Our product candidates are targeting cancer, dermatitis, osteoarthritis pain and obesity in pets. Our lead product candidate, AKS-701d, is an antibody for canine bladder cancer. We have a manufacturing plant in Beverly, Massachusetts. The companion animal therapeutics market is projected to grow to $23.7 billion in 2025 – up from $12.5 billion in 2015, according to the American Pet Products Association. Our current product portfolio includes multiple product candidates consisting of large molecule biologics that are designed to target significant opportunities in serious medical conditions in pets such as urothelial carcinoma (bladder cancer) in dogs, atopic dermatitis in dogs, chronic pain associated with arthritis in dogs, and obesity and metabolic disease in cats. Our lead technologies are built around the Ambifect® immuno-enhancing protein platform and a growing portfolio of targeted precision proteins. Our proprietary Ambifect® technology platform is designed to harness the animal’s own cells to produce therapeutic levels of targeted antibodies, leveraging the immune system to sustain long-term antibody production through simple intramuscular injection. Our business strategy focuses on staged risk-reduction and early revenue opportunities. We are pursuing conditional U.S. Department of Agriculture, or USDA, Center for Veterinary Biologics, or CVB, approval for AKS-701d, a Programmed Death- Ligand 1, or PD-L1-targeting monoclonal antibody for bladder cancer in dogs, and AKS-619d, an Ambifect®-based follow-on product with the same target, intended to reduce dosing level and frequency and expand indications. Additional candidates in development include AKS-699 for canine atopic dermatitis, AKS-548d for osteoarthritis-associated chronic pain, and AKS-562c, a long-acting Glucagon-Like Peptide-1, or GLP-1 precision protein for feline obesity. Note: Net loss and revenues are for the 12 months that ended on June 30, 2025. (Note: Akston Biosciences filed its S-1 for its IPO on Oct. 8, 2025, and disclosed the terms: The company is offering 2.2 million shares at a price range of $8.00 to $10.00 to raise $19.8 million.)
Industry:	Veterinary Pharmaceuticals - For Pets
Employees:	68
Founded:	2011
Contact Information
Address	100 Cummings Center, Suite 454C Beverly, MA 01915
Phone Number	(978) 969-3381
Web Address	https://www.akstonbio.com/
View Prospectus:	Akston Biosciences
Financial Information
Market Cap	$98.99mil
Revenues	$7.0 mil (last 12 months)
Net Income	$-11.52 mil (last 12 months)
IPO Profile
Symbol	AXTN
Exchange	NYSE - American
Shares (millions):	2.2
Price range	$8.00 - $10.00
Est. $ Volume	$19.8 mil
Manager / Joint Managers	ThinkEquity
CO-Managers
Expected To Trade:
Status:	TBA
Quiet Period Expiration Date:	Available only to Subscribers
Lock-Up Period Expiration Date:	Available only to Subscribers
SCOOP Rating	Available only to Subscribers
Rating Change	Available only to Subscribers

Akston Biosciences

(Incorporated in Delaware)

We have a manufacturing plant in Beverly, Massachusetts.

The companion animal therapeutics market is projected to grow to $23.7 billion in 2025 – up from $12.5 billion in 2015, according to the American Pet Products Association.

Note: Net loss and revenues are for the 12 months that ended on June 30, 2025.

(Note: Akston Biosciences filed its S-1 for its IPO on Oct. 8, 2025, and disclosed the terms: The company is offering 2.2 million shares at a price range of $8.00 to $10.00 to raise $19.8 million.)